文献速递妇科

在加州北部某医疗系统内简化卵巢癌女性的基因检测流程

Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
PubMed 文献 · Gynecol Oncol · 2020-08-07

这项前瞻性试点研究于2019年5月1日至11月6日在两家妇科肿瘤中心开展,由妇科肿瘤医生直接向新诊断卵巢癌女性提供多基因 panel 检测,随后选择性遗传咨询。40例参与者全部完成检测,其他中心101例中85%被转诊遗传学(p=.0061)、67%完成检测(p<.0001)。结论认为在妇科肿瘤诊疗点进行基因检测可行,可提高检测接受率并缩短出结果时间。

要点

  • 妇科肿瘤医生直接提供多基因 panel 检测,40例参与者全部完成检测。
  • 其他中心101例中85%被转诊遗传学、67%完成检测,与试点组差异有统计学意义。
  • 试点组诊断至采血18.5天、至结果通知34天,其他中心分别为25.5天和53天。

核心结论

  • 在妇科肿瘤诊疗点对卵巢癌患者进行基因检测是可行的,可提高检测接受率并改善出结果时间。

研究设计与样本

  • 前瞻性试点研究,2019年5月1日至11月6日在整合医疗系统的两家妇科肿瘤中心开展。
  • 妇科肿瘤医生向新诊断卵巢癌女性提供多基因 panel 检测,随后进行选择性遗传咨询。
  • 将研究参与者与医疗系统内其他中心的女性进行比较,试点组40例,其他中心101例。

主要发现

  • 试点组40例全部接受并完成基因检测。
  • 其他中心101例中85%被转诊至遗传学(与试点参与者比较 p=.0061),67%完成检测(p<.0001)。
  • 试点组诊断至采血和至结果通知分别为18.5天和34天,其他中心分别为25.5天和53天。
  • panel 检测在试点组检出9例(22.5%)致病性突变,在其他中心检出7例(10.3%,p=.08)。
  • 患者和提供者对简化流程高度满意。

临床怎么用

  • 作者结论认为,在妇科肿瘤诊疗点对卵巢癌患者进行基因检测可行,可提高检测接受率并改善出结果时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Referral to Genetics for pre-testing counseling may be inefficient for women with ovarian cancer. This study assesses feasibility of gynecologic oncologists directly offering genetic testing. METHODS: A prospective pilot study was conducted at two gynecologic oncology hubs in an integrated healthcare system from May 1 to November 6, 2019. Gynecologic oncologists offered multigene panel testing to women with newly diagnosed ovarian cancer, followed by selective genetic counseling. Outcomes were compared between study participants and women from other hubs in the health system. RESULTS: Of ovarian cancer patients at study sites, 40 participated and all underwent genetic testing. Of 101 patients diagnosed at other sites, 85% were referred to genetics (p = .0061 compared to pilot participants) and 67% completed testing (p < .0001). The time from diagnosis to blood draw and notification of result was 18.5 and 34 days for the pilot group compared to 25.5 and 53 days at other sites. Panel testing detected 9 (22.5%) and 7 (10.3%, p = .08) pathogenic mutations in each group, respectively. Patients and providers were highly satisfied with the streamlined process. CONCLUSION: Genetic testing performed at the gynecologic oncology point of care for patients with ovarian cancer is feasible, increases uptake of testing, and improves time to results.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Powell CB, Laurent C, Ciaravino G, et al. Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. Gynecol Oncol. 2020. PMID: 32778409. doi:10.1016/j.ygyno.2020.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。